Metabolic relationship between diabetes and Alzheimer's Disease affected by Cyclo(His-Pro) plus zinc treatment

BBA clinical Pub Date : 2017-06-01 DOI:10.1016/j.bbacli.2016.09.003

Moon K. Song , David S. Bischoff , Albert M. Song , Koichi Uyemura , Dean T. Yamaguchi

{"title":"Metabolic relationship between diabetes and Alzheimer's Disease affected by Cyclo(His-Pro) plus zinc treatment","authors":"Moon K. Song , David S. Bischoff , Albert M. Song , Koichi Uyemura , Dean T. Yamaguchi","doi":"10.1016/j.bbacli.2016.09.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Association of Alzheimer's Disease (AD) with Type 2 Diabetes (T2D) has been well established. Cyclo(His-Pro) plus zinc (Cyclo-Z) treatment ameliorated diabetes in rats and similar improvements have been seen in human patients. Treatment of amyloid precursor protein (APP) transgenic mice with Cyclo-Z exhibited memory improvements and significantly reduced Aβ-40 and Aβ-42 protein levels in the brain tissues of the mice.</p></div><div><h3>Scope of review</h3><p>Metabolic relationship between AD and T2D will be described with particular attention to insulin sensitivity and Aβ degradation in brain and plasma tissues. Mechanistic effect of insulin degrading enzyme (IDE) in decreasing blood glucose and brain Aβ levels will be elucidated. Cyclo-Z effects on these biochemical parameters will be discussed.</p></div><div><h3>Major conclusion</h3><p>Stimulation of IDE synthesis is effective for the clinical treatment of metabolic diseases including AD and T2D.</p></div><div><h3>General significance</h3><p>Cyclo-Z might be the effective treatment of AD and T2D by stimulating IDE synthesis.</p></div>","PeriodicalId":72344,"journal":{"name":"BBA clinical","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.bbacli.2016.09.003","citationCount":"35","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BBA clinical","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2214647416300393","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 35

Abstract

Background

Association of Alzheimer's Disease (AD) with Type 2 Diabetes (T2D) has been well established. Cyclo(His-Pro) plus zinc (Cyclo-Z) treatment ameliorated diabetes in rats and similar improvements have been seen in human patients. Treatment of amyloid precursor protein (APP) transgenic mice with Cyclo-Z exhibited memory improvements and significantly reduced Aβ-40 and Aβ-42 protein levels in the brain tissues of the mice.

Scope of review

Metabolic relationship between AD and T2D will be described with particular attention to insulin sensitivity and Aβ degradation in brain and plasma tissues. Mechanistic effect of insulin degrading enzyme (IDE) in decreasing blood glucose and brain Aβ levels will be elucidated. Cyclo-Z effects on these biochemical parameters will be discussed.

Major conclusion

Stimulation of IDE synthesis is effective for the clinical treatment of metabolic diseases including AD and T2D.

General significance

Cyclo-Z might be the effective treatment of AD and T2D by stimulating IDE synthesis.

查看原文本刊更多论文

Cyclo(His-Pro)加锌治疗对糖尿病和阿尔茨海默病代谢关系的影响

背景:阿尔茨海默病(AD)与2型糖尿病(T2D)的关联已经得到了很好的证实。cycloo (His-Pro)加锌(cycloz)治疗可以改善大鼠的糖尿病，在人类患者中也有类似的改善。淀粉样蛋白前体蛋白(APP)转基因小鼠经环z处理后，记忆力得到改善，脑组织中a - β-40和a - β-42蛋白水平显著降低。AD和T2D之间的代谢关系将特别关注脑和血浆组织中的胰岛素敏感性和Aβ降解。阐明胰岛素降解酶(IDE)在降低血糖和脑Aβ水平中的作用机制。我们将讨论环- z对这些生化参数的影响。结论刺激IDE合成可有效治疗AD、T2D等代谢性疾病。环氯- z可能通过刺激IDE的合成而有效治疗AD和T2D。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BBA clinical

自引率

0.00%

发文量

文献相关原料

公司名称	产品信息	采购帮参考价格